Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $62.00 | Overweight → Equal-Weight | Morgan Stanley |
| 5/13/2025 | $47.00 | Market Perform → Underperform | Leerink Partners |
| 10/7/2024 | $58.00 → $62.00 | Overweight → Equal Weight | Wells Fargo |
| 9/19/2024 | $52.00 → $57.00 | Overweight → Neutral | JP Morgan |
| 6/7/2024 | $48.00 → $51.00 | Overweight → Neutral | Piper Sandler |
| 2/29/2024 | $54.00 | Outperform | TD Cowen |
| 7/24/2023 | $61.00 | Buy | H.C. Wainwright |
| 7/24/2023 | $43.00 → $45.00 | Buy → Neutral | Goldman |
SCHEDULE 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks. "Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth," said Dr. Helen To
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences. Details on the Company's participation are as follows: Event: Benchmark 2025 Healthcare House Call Virtual Conference Format: 1x1 Meetings Date: Thursday, May 29, 2025 Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Format: Fireside Chat and 1x1 Meetings Date: Monday, June 9, 2025 Presentation Time: 7:00am PT / 10:00am ET A live audio webcast of the presentation will be available in the Investor Relations sec
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equal-Weight and set a new price target of $62.00
Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and set a new price target of $47.00
Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.
SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks. "Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth," said Dr. Helen To
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal
SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)